Leadership Team

Kevin J. Knopp, PhD

CEO & Co-founder

Dr. Kevin Knopp is a co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.

Christopher D. Brown, PhD

CTO & Co-founder

Dr. Chris Brown is a co-founder, VP and CTO of 908 Devices Inc. Prior to founding 908 Devices, Chris was a platform architect at Apple in California leading investigations into future-gen hardware/software technologies. Before joining Apple, he headed Product Development and Engineering at Ahura Scientific and later Thermo Fisher Scientific, which acquired Ahura Scientific in 2010. Joining Ahura in 2004 he established the company’s core embedded analytics and chemometrics capability, led product and market development for the pharmaceutical/industrial vertical, and established the international applications, and scientific support teams. Prior to Ahura, Chris held several senior leadership roles at InLight Solutions developing multiple clinical, in-vivo and non-invasive biodiagnostic products across a range of imaging and spectroscopic modalities. He has published some 150 papers and presentations, and more than 30 granted/pending patents. Chris received his B.Sc. from Brandon University and Ph.D. in Chemistry from Dalhousie University where he developed chemometric techniques for mass spectrometry and chromatography.

Joseph H. Griffith

Chief Financial Officer

Mr. Joe Griffith joins 908 Devices as Chief Financial Officer supporting the development of strategic business plans and financial metrics. Joe brings a 17-year management background in corporate and operational finance, accounting and administration. Most recently he served as Chief Financial Officer for PerkinElmer’s Life Science division. Previously, Joe served in numerous roles for Caliper Life Sciences including Chief Accounting Officer, VP of Finance and Corporate Controller. Joe achieved a BS in Accounting from Villanova University and holds Certified Public Accountant status in Pennsylvania.

Michele Fournier

Chief People Officer

Michele Fournier is Chief People Officer bringing more than thirty years of Global HR experience in corporate and consulting roles, both in the United States, Asia and Europe. having completed several short-term expat assignments in various European and Asian offices.  She has extensive experience establishing and promoting compensation and benefits strategies which include working with Board of Directors and Compensation Committees and Shareholder services. She also has deep experience in the areas of M&A, Corporate strategy, executive compensation, employee relations, HR shared services, change management, employee benefits, equity and incentive program design, talent management, and HR and organizational transformation. Michele has held a variety of senior HR leadership roles including Executive Vice President and Chief Human Resources Officer and Corporate Vice President, Compensation, Benefits and HRIS at Parexel International, a Clinical Research Organization in Newton, Massachusetts, and as Corporate Vice President of Global Human Resources and Corporate Services at PTC, a Product Lifecycle Management technology company in Boston, Massachusetts.  Her previous roles include consulting and Compensation and Benefit leadership positions at Cambridge Technology Partners (CTP), William M. Mercer, and Medtronic.  Ms. Fournier earned her BA from the University of Michigan and is a Certified Compensation Professional (CCP).

John Kenneweg

VP, Government

John Kenneweg is Vice President of our Government business. A veteran of the industry, John has over 17 years of successful sales and marketing experience, directing sales and business development efforts for innovation leaders such as Draeger, Ahura Scientific and Thermo Fisher Scientific. Most recently, John held the position of Director of Federal Government Programs at Thermo Fisher Scientific’s Portable Analytical Instrument business where he generated significant growth across multiple product platforms. He was part of the original Ahura Scientific sales team that successfully launched the first handheld Raman and FTIR spectrometers. He has been successful in developing markets for multiple new technologies and solutions to the safety and security market to include federal agencies, military organizations and civilian emergency responders. John graduated from West Virginia University and served in the United States Marine Corps.

Trent Basarsky, PhD

VP, Corporate Development

Dr. Trent Basarsky is the Vice President of our Corporate Development. Trent is a marketing and business executive with more than 20 years of experience in the life sciences sector. Prior to joining 908 Devices, Trent was the Chief Business Officer at Zephyrus Biosciences, the developers of a single cell western platform, which was acquired by BioTechne in 2016. Previously Trent was the VP of Corporate Development at ProteinSimple, a company focused on protein analysis instrumentation, where his responsibilities in corporate development, marketing and intellectual property helped grow the company to over $55M in revenue prior to the successful sale of the company for $300M. Trent served as the Director of Corporate Development at Codexis, a cleantech company focused on next-generation biofuels and pharmaceutical manufacturing. Before joining Codexis, he was Director of Corporate Development at Molecular Devices and helped grow the business to more than $180M prior to the sale of the company for over $600M. He also held positions in marketing, product management, business development and intellectual property at Axon Instruments, which was acquired by Molecular Devices. Trent holds a Ph.D. in Neuroscience from Iowa State University, a B.Sc. in Zoology from the University of Alberta, and is a registered patent agent. He enjoys endurance mountain bike racing, playing competitive hockey, and golf.

Kevin McCallion, PhD

VP of Production & NPI

Mr. Kevin McCallion is the VP of Production and New Product Introduction. Prior to 908 Devices, Kevin served as VP of Engineering for TeraDiode, a developer of compact, high efficiency laser sources and was the Director of Engineering at Finisar Corp, a manufacturer of optical communications subsystems and components. Prior to that, he was a co-founder and VP of Product Development at Azna LLC, implementing novel, high-speed diode lasers for long haul transmission. Earlier in his career, he also held senior technical management positions at Nortel Networks and CoreTek, Inc. He received a BEng (1st Hons), MSc and PhD degrees in Electrical Engineering and Optoelectronics from the University of Strathclyde in the UK. Mr McCallion is an inventor on more than 30 US patents and is author on numerous technical publications.

Maura Fitzpatrick

VP of Product Management and Marketing

Maura Fitzpatrick is the Vice President of Product Management and Marketing. She is a passionate product and marketing executive with more than 20 years’ experience in accelerating product development and creating new markets for organic growth. Maura has a strong background in leading product and marketing teams across multiple markets including life science, forensics, photonics, semiconductor, and industrial sectors for global companies such as Waters, Thermo Fisher Scientific, Ahura Scientific and General Electric. Maura earned a BS in Chemistry from Merrimack College and an AS in Marketing from Johnson and Wales University.

Michael Turner

VP and General Counsel

Michael Turner is Vice President and General Counsel bringing more than 20 years of corporate, securities and governance experience to the role.  Previously Michael served as Co-Chief Executive Officer, General Counsel and Executive Director of Allied Minds plc, a publicly traded venture firm focused on early stage company development within the technology and life science sectors. Prior to that, he served as a law firm Partner at each of DLA Piper LLP and Goodwin Procter LLP, counseling public and private companies, investment banks, and private equity and venture capital firms, with an emphasis on capital markets, mergers and acquisitions and corporate governance for growth companies in the technology and life science sectors. Michael received his B.A. from Colgate University and his J.D. from Cornell Law School and is admitted to the bar in Massachusetts and New York.

Steve Davenport

VP, Commercial Sales

Steve Davenport is our Vice President of Commercial business, bringing more than 30 years sales and management experience in the life sciences industry to the team.  Prior to joining 908 Devices Steve was Head of Life Science Research sales at Sartorius leading the division to record sales growth in 2020 and has been instrumental in development of the global Bioanalytics sales organization consistently delivering high double digit sales growth since he joined Sartorius via the acquisition of Intellicyt Corporation in 2016.  Throughout his career Steve has been involved in successful market introductions of multiple drug discovery, protein, cell and genetic analysis technologies and the development of high performing sales organizations at Amersham Pharmacia Biotech (now Cytiva), Molecular Devices (now Danaher) and ProteinSimple (now Biotechne).  Steve has Bsc. in Applied Chemistry from the University of Wales Institute of Science and Technology.  During his spare time Steve runs marathons, enjoys watching virtually any sport, playing golf and testing out his cookery on friends and family.

"Over the last 9 years we have assembled a talented team that brings a unique and insightful viewpoint to everything we do. I am proud to work with a team that is focused, driven to innovate, and has fun along the way."
Kevin J. Knopp, CEO

Steve Araiza

Co-founder & Software Architect

Mr. Steve Araiza is a co-founder of 908 Devices and serves as Director of Software. He has over 15-years of software engineering and architecture experience. He has delivered products in such diverse applications as medical devices, and distributed software systems however, he has particular expertise in all aspects of handheld analytical tools. Steve has led design and implementation of the software architecture for multiple analytical handheld product platforms. This work spanned design, architecture, embedded systems and user interface from concept through implementation. In addition, Steve has consulted on and delivered software solutions for over 25 companies including Ahura Scientific, Adaptive Optics, Agilent, Light Lab Imaging (now St. Jude Medical), Raytheon and Philips Medical. Steve earned his B.S.E.E from California State University.

Andrew Bartfay

Co-founder & Director, Hardware Development

Mr. Andy Bartfay is a co-founder of 908 Devices and serves as Director of Hardware Development. His 25 years of electronics design experience spans a diverse range of applications and technologies. In particular, he has significant experience with integrated systems for handheld and portable platforms and has been responsible for the complete electronic design of several successful handheld products. His specific capabilities include chip and board-level design, high speed digital and mixed signal design, embedded computers and firmware, high reliability and mil-spec systems, all aspects of electronic product manufacturing, and agency approval testing. Andy has supplied design services or complete products to a broad range of customers including Perkin Elmer, Ahura Scientific, Philips Medical, Boeing, Disney, Lockheed and the US government. Andy earned his B.S. in Electrical Engineering from the University of Rochester and has two patents granted or pending.

Michael Jobin

Co-founder & Director, Product Development

Mr. Michael Jobin is a co-founder of 908 Devices and leads mechanical engineering and design efforts. He has 27 years of experience in instrumentation, medical and consumer markets. As Director of Engineering at Altitude, Inc. a leading product development firm, he led design and mechanical engineering on numerous groundbreaking handheld instruments and tools for Ahura Scientific, Niton Corporation and DeWALT. Through this work, Michael has been instrumental in the successful transition of multiple technologies including Raman, FTIR and XRF techniques from laboratory to field use. Michael was the co-founder and Chief Technology Officer of MicroBiosciences, a Boston based startup developing microfluidics instruments for medical research. Michael holds 23 patents, and has several applications pending. He earned a BS in Mechanical Engineering and a BFA in Industrial Design from the University of Michigan.

Scott Miller, PhD

Co-founder & Director, MS Engineering

Dr. Scott Miller is a co-founder of 908 Devices and serves as Director of Mass Spectrometer Engineering, leading applications and system integration efforts. Prior to joining 908 Devices, Scott was Principal Development Engineer at Ahura Scientific and at Thermo Fisher Scientific following acquisition. He led several multi-million dollar government-funded R&D projects. These projects were focused on development of portable, easy-to-use analytical instruments for chemical and biological detection and identification. Prior to joining Ahura Scientific, Scott was Principal Scientist at BioProcessors Corp. where he developed automated, microscale cell culture systems. He has authored over a dozen peer-reviewed articles and has several patents pending. Scott received his Ph.D. in Physical Chemistry from Northwestern University and held a postdoctoral position at MIT.

Board of Directors

Nicolas Barthelemy

Nicolas Barthelemy is a life science industry veteran with 25 years of diverse expertise. He brings extensive experience in manufacturing, distributing and commercializing life science instruments, reagents and services, and knowledge of the research, clinical and bioprocessing markets as well as his public and private board experience. Mr. Barthelemy previously served as the President and Chief Executive Officer of Biotheranostics, Inc., a Molecular Diagnostics company. Prior to joining Biotheranostics, he held a variety of senior executive roles at Life Technologies until its acquisition by Thermo Fisher Scientific, including Chief Commercial Officer and President of the Cell Systems Division. Prior to joining Invitrogen (which later became Life Technologies), Mr. Barthelemy held a variety of operational and commercial roles with Biogen, Inc., including Vice President of Manufacturing. Before that, he held various technical positions at Merck & Co’s manufacturing division. Mr. Barthelemy currently serves on the board of directors of Repligen, Fluidigm and Genewiz and has previously served on the board of directors of Essen Bioscience. He holds an engineering degree from École Supérieure de Physique et Chimie Industrielles, France, as well as a master’s degree in chemical engineering from the University of California, Berkeley.

Keith L. Crandell

Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory.

Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace. Mr. Crandell also serves as a director of the Illinois Venture Capital Association.

Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Fenel Eloi

Fenel Eloi is a highly seasoned life science executive experienced in leading the transformation of small and mid-size companies to large operating global organizations.  During his professional career, Fenel has scaled up operations, expanded businesses both organically and through strategic partnerships and completed a number of public and private financing transactions.  He was most recently the Chief Financial Officer and then Chief Operating Officer of Cell Signaling Technology, Inc., a privately held life sciences company, where he oversaw significant growth of the business over a period of 12 years and provided leadership in the transformation of the company to a global operation.  Prior to that, he was the Chief Operating Officer and Chief Financial Officer of Interleukin Genetics, Inc., a formerly NASDAQ-listed diagnostic company, for 5 years.  Prior to Interleukin, he was Chief Financial Officer at LifeCell Corp and Genome Therapeutics Corp, both formerly NASDAQ-listed companies, for a combined period of twelve years.    

Fenel currently serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company, where he serves as Chair of the Audit Committee, of CompleteCare IT, a privately held IT service company, and of the Museum of Science in Boston, and is a Managing Partner at P&M Capital Partners.  Fenel previously served on the board of Cell Signaling Technology, Inc., a reagents company, and BioHelix Corporation, a diagnostics company.

Fenel has an MBA from Anna Maria College and a BA in Business and Finance from Lee University.

Jeff George

Jeff George has two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. Between 2008 and 2016, Jeff served on the Executive Committee of Novartis Group, first as CEO and Division Head of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharmaceutical and biosimilar subsidiary. He was then CEO and Division Head of Texas- based Alcon, Novartis’s ~$10 billion revenue ophthalmology subsidiary. More recently, he served as CEO and Board Director of Performance Health, a global manufacturer and distributor to the physical therapy, rehab, and sports medicine markets.

Earlier his career, Jeff served as head of Emerging Markets at Novartis Pharmaceuticals, as Vice President and Head of Western & Eastern Europe for Novartis Vaccines, as a Senior Director of Strategic Planning & Business Development at Gap Inc., and as an Engagement Manager with McKinsey & Co.

Jeff currently serves on the board of directors at Amneal Pharmaceuticals (NYSE: AMRX), a leading specialty and generic pharma company; Wishbone Medical, a global leader in pediatric orthopedic medical devices; and Dorian Therapeutics, a pre-clinical biotech firm in the cellular anti-senescence field. He also serves the boards of several leading non-profit organizations including Education Opens Doors, where he is Chairman, the North Texas Food Bank, and YPO of Dallas. Jeff previously served on the board of Roam Analytics, an artificial intelligence healthcare software firm, and AdvaMed, the medical device industry association.

Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded in 2017, and an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm.

Jeff holds an MBA from Harvard Business School, a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), and a B.A. in international relations from Carleton College.

Kevin Hrusovsky

Kevin Hrusovsky, Chairman of 908 Devices’ Board of Directors and Chairman & CEO of Quanterix Corporation (QTRX) is an American entrepreneur and healthcare visionary, who has dedicated his 30-year career to leading disruptive medical technology companies and shepherding a global movement to transform healthcare to Precision Health. He created Powering Precision Health foundation, an internationally renowned non-profit promoting a new era of medicine using biomarker innovation to achieve precision medicine. He is regarded as a pioneer, accelerating adoption and value creation for many “game changing” non-invasive early detection technologies for Oncology, Neuro-Degeneration and Cardiology which are transforming drug development and disease prevention.  Before QTRX, he was CEO of Caliper Life Sciences (CALP – acquired by PKI), and Zymark Corporation (acquired by CALP), as well as, President of Life Sciences at PerkinElmer (PKI). He also held senior roles at FMC Corp and DuPont. His numerous board memberships include both public and privately held companies as well as educational, healthcare and technology non-profit organizations. He is the recipient of several distinguished awards including the 2019 EY Entrepreneur of the Year®,  2017 BBJ Innovation All-Star award for transforming the practices of medicine and health, the 2018 Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University and received an Honorary Doctorate from Framingham State University for contributions to life sciences.

Kevin J. Knopp, PhD

Dr. Kevin Knopp is a co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.

Mark Spoto

At Razor’s Edge, Mr. Spoto is responsible for the fund’s day-to-day business operations. His primary responsibilities include the identification and evaluation of investment opportunities, market and industry analyses, deal structuring, fundraising, and LP relations, as well as support of and advice to Razor’s Edge portfolio companies. Prior to joining Razor’s Edge, Mr. Spoto was a partner in the Reston, Virginia office of Cooley LLP, a national law firm. He worked with many emerging and high growth technology companies and investment funds, and his practice focused on mergers and acquisitions, venture capital, private equity and public securities offerings, and general corporate representation. His operating company clients were engaged in high-growth industry sectors including software, government contracts, aerospace/defense, telecommunications, and media. From 2008-2011, Chambers USA named Mr. Spoto to its list of America’s Leading Lawyers for Business, and in 2009, he was selected by The Legal 500 as a leading lawyer in the fields of venture capital and emerging companies. Prior to practicing law, Mr. Spoto was an aerospace engineer, working on the Air Force Titan IV rocket program for McDonnell Douglas Space Systems Company. He holds a B.S. in Aerospace Engineering from Boston University and a J.D. from Georgetown University Law Center.

Dr. Marcia Eisenberg

Dr. Marcia Eisenberg, chief scientific officer, Labcorp Diagnostics has extensive experience with forensic DNA testing, biotechnology, molecular genetics and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp (NYSE: LH), a global life sciences company. Dr. Eisenberg previously held roles on the National Institute of Environmental Health Sciences and the FBI’s National DNA Advisory Board, where she was later recognized for her contributions to the advancement of DNA technology.   A molecular biologist by training, Dr. Eisenberg was a member of the team responsible for commercializing polymerase chain reaction (PCR) tests in the 1990s, making large-scale testing possible. Over the last year, she has led the effort at Labcorp and across the industry to use that same technology to make high-quality testing for COVID-19 broadly available. She is highly regarded within the industry and has been instrumental in developing innovations in diagnostics and patient care, improving the health and lives of people around the globe. Earlier this year, Dr. Eisenberg was recognized by the Healthcare Businesswomen’s Association (HBA) as a 2021 Luminary.


Jay Flatley

Executive Chairman Illumina, Inc.

James W Jorgenson, PhD

William Rand Kenan, Jr. Distinguished Prof. of Chemistry at UNC Chapel Hill

Douglas Kahn

Chairman of Tetragentics, Inc.

Alan G. Marshall, PhD

Robert O. Lawton Professor of Chemistry and Biochemistry at Florida State University

Steven Reeves

Former DoD Joint Program Executive Officer for CBRND

Nicolas H. Roelofs, PhD

Former President Life Sciences Group, Agilent Technologies

Daryoosh Vakhshoori, PhD

Founder & CEO, Pendar Technologies

David Walt, PhD

Wyss Professor of Biologically Inspired Engineering at Harvard Medical School

Jimmie Oxley

Professor of Chemistry at the University of Rhode Island

Jarrod Marto

Associate Professor of Pathology at Harvard Medical School

Joshua Coon

Professor of Chemistry and Biomolecular Chemistry at UW-Madison

Martin D. Madaus, PhD

Chief Executive Officer at Ortho-Clinical Diagnostics, Inc.

Paul Meister

Co-Founder of Liberty Lane Partners